Related Experiment Video
Updated: May 6, 2026
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Results of the 4D study: ten years of follow-up?
Christoph Wanner1, Kai-Renke Schmidt, Vera Krane
1Division of Nephrology, Department of Medicine, University Hospital of Würzburg and the Comprehensive Heart failure Center, Oberdürrbacherstr. 2, 97080, Würzburg, Germany, wanner_c@medizin.uni-wuerzburg.de.
Insights
Statins offer uncertain cardiovascular benefits for hemodialysis patients. Individualized decisions consider factors like cholesterol levels, comorbidities, and life expectancy, especially in Japan.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hemodialysis patients face high cardiovascular risk.
- Current guidelines (KDIGO) do not recommend statin initiation for most hemodialysis patients.
- Existing trials (4D, AURORA) have limitations in age and risk stratification.
Purpose of the Study:
- To evaluate the clinical benefit of statin regimens in hemodialysis patients.
- To inform individualized treatment decisions regarding statin use.
Main Methods:
- Review of existing evidence and clinical trial data (4D, AURORA).
- Analysis of factors influencing statin benefit in this population.
- Consideration of patient-specific variables and guideline recommendations.
Main Results:
- Statin treatment offers an uncertain, though potentially small, reduction in cardiovascular events.
- High low-density lipoprotein cholesterol may increase potential statin benefit.
- Factors like comorbidities, pill burden, recent myocardial infarction, and life expectancy influence treatment decisions.
Conclusions:
- Individualized statin treatment decisions are warranted for hemodialysis patients.
- Patient and physician discussions should weigh potential benefits against risks and individual factors.
- Specific patient profiles, such as those with very high LDL-C or greater life expectancy (particularly in Japan), may favor statin use.
Abstract:
Despite the exceedingly high cardiovascular risk in hemodialysis patients, it is uncertain whether statin regimens lead to clinical benefit in this population. KDIGO (Kidney Disease Improving Global Outcomes) guidelines summarize the evidence, stating that initiation of statin treatment is not recommended for most prevalent hemodialysis patients. Since the 4D and AURORA trials did not cover all age and risk ranges, an individualized treatment approach is accepted. Thus, patients and physicians may reasonably choose statin treatment if they are interested in an apparent, but relatively small, uncertain reduction in cardiovascular events. Since very high low-density lipoprotein cholesterol might increase the likelihood of benefit from statins in a dialysis patient, patients who meet this criterion may be more inclined to receive a statin. Other factors that might influence a patient's decision to receive statins could include more severe comorbidity or higher current pill burden-both favoring non-treatment--and recent myocardial infarction or greater life expectancy-both favoring treatment. The latter may be especially true for dialysis patients in Japan.
More Related Videos
08:02Author Spotlight: Enhanced Quantification of Cardiovascular Calcification Progression for Longitudinal Micro PET/CT Studies in Small Research Animals
Published on: November 15, 2024
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Related Concept Videos
02:20Longitudinal Research
01:26Longitudinal Studies